Robinson+Cole Represents Prime Number Acquisition I Corp. in Complex deSPAC Transaction with noco-noco Pte. Ltd.

Robinson+Cole is pleased to announce that it has represented Prime Number Acquisition I Corp. (PNAC) in the closing of its business combination with noco-noco Pte. Ltd. (noco-noco), a Singapore developer of decarbonization solution technologies. The transaction, valuing the post-combination combined entity at $1.35 billion, was announced on December 29, 2022, and was closed on August 25, 2023. The combined public company, noco-noco Inc. (Nasdaq: NCNC), commences trading on the Nasdaq Capital Market on Monday, August 28, 2023.

The team advising on the transaction, led by Arila E. Zhou, included Capital Market + Securities Team members Ze’-ev E. Eiger, Tiange (Tim) Chen, Yi (Tiffany) Liu and Christopher F. Homsy. The cross-disciplinary team was also supported by Business Transactions Group lawyer Eric M. Kogan, Intellectual Property + Technology Group co-chair Jacqueline Pennino Scheib, and Group member Nicole M. Diodati. Read more.

Robinson+Cole Represents Medacist in its Acquisition by Thoma Bravo

Robinson+Cole served as legal counsel to Medacist, a pioneer in drug diversion monitoring, in its acquisition by Thoma Bravo, a leading software investment firm in a strategic growth investment in Bluesight, the Medication Intelligence™ Company, which closed July 17, 2023. The investment is expected to further enhance Bluesight's drug diversion prevention and continue to grow Bluesight's inventory management and spend optimization offerings. Bluesight's acquisition of Medacist combines two innovators in drug diversion analytics and medication management solutions that together will serve more than 2,000 hospitals across North America. The complex deal was led by Transactional Health Law Group co-chair Les Levinson and supported by a cross-disciplinary team of R+C lawyers, including Adam Anderson, Jackie Scheib, Michael Kearney, Virginia McGarrity, Natale DiNatale, Ben Jensen, Chris Homsy, Jon Cabot and Nicole Diodati. For more information, view the press release.

Capital Markets + Securities Team Pleased to Represent Feutune Light Acquisition Corporation in IPO

Robinson+Cole’s Capital Markets + Securities Team (the Team) represented Feutune Light Acquisition Corporation, a newly organized blank check company, in completing its initial public offering on June 21, 2022 of 9,775,00 units at an offering price of $10.00 per unit, which includes 1,225,000 units issued pursuant to the full exercise of the underwriter’s over-allotment option, for aggregate gross proceeds to the Company of $97.75M. The units began trading on the Nasdaq Global Market under the ticker symbol “FLFVU” on June 16, 2022. The Team members advising on the offering were Arila Zhou, Tim Chen, Christopher Homsy, Yang Xu and Samuel Maduabueke. Read more.

Business Transactions Team Represents SmartEquip in Sale to Ritchie Bros.

Robinson+Cole’s Business Transactions Team represented SmartEquip, Inc., a multi-manufacturer technology platform that provides customers with service and diagnostic support to each asset in their fleet, as well as enabling the electronic procurement of parts from OEMs and their dealers, in connection with its sale to Ritchie Bros., a global asset management and disposition company, for a purchase price of approximately $175 million. The R+C team included Adam Anderson, Stephen E. Cooper, Jacqueline Pennino Scheib, Virginia E. McGarrity, Christopher F. Homsy, Kayla C. O’Leary, Kathleen M. Porter, Michael J. Kearney, Jr. and Eric M. Kogan. The sale closed on November 2, 2021. Read more about the transaction.